Genentech & Biogen Idec get complete response letter from US FDA for Rituxan to treat CLL
Saturday, November 21, 2009 09:00 IST South San Francisco, California
Genentech, Inc, a wholly-owned member of the Roche Group and Biogen Idec announced that the US Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan (rituximab) plus fludarabine
